Scientists consider fungal infection vax from yeast; The vaccination-tracking nightmare;

Vaccine Research

Scientists found that mice injected with baker's yeast could survive high doses of aspergillosis, a fungal infection that causes kidney and liver failure in patients with weak immune systems by attacking their lungs. The mice received three doses a week apart of the yeast, and could be used to develop a vaccine against fungal infections. News

Vaccine Market

While Inovio posted a $2.8 million net loss for the second quarter, its revenues more than doubled, rising to $2.4 million from $1.1 million in Q2 2010. Report

The Federal Commission for the Protection Against Sanitary Risk for the Mexico Ministry of Health has awarded the GMP certificate to Sinovac for its seasonal flu vaccine and hepatitis A vaccine. Sinovac release

Cumberland County, NC, health officials have vaccinated nearly 2,000 individuals who may have been exposed to hepatitis A at a local Olive Garden. So far, only the infected employee has been ill. Item

Emergent BioSolutions announced it had a profit of $14.2 million during the second quarter, thanks mostly to sales of its BioThrax anthrax vaccine. The company's total revenue hit $71.5 million, a 28% increase from the year previous. Report

And Finally... M. Katie Charles, a graduate student at Johns Hopkins' Bloomberg School of Public Health, wrote a piece for the Huffington Post on the difficulties of tracking vaccinations, both by the individual and physicians. More

Suggested Articles

Former FDA Commissioner Scott Gottlieb says 40% of the population needs to be vaccinated to achieve COVID-19 herd immunity.

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.